---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-24-000029"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T12:29:01.789445+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arcutis Q4 2023 revenue $13.5M (+357% YoY), net loss $66.3M; ZORYVE foam launched

## Summary
- Q4 net product revenue $13.5M vs $3.0M Q4 2022, driven by 67% sequential demand growth and GTN improvement.
- Full-year 2023 total revenue $59.6M (incl. $30.4M Huadong upfront); net loss $262.1M ($3.78/share).
- R&D expenses fell 39% to $110.6M; cash & securities $272.8M as of Dec 31, 2023.
- FDA approved ZORYVE foam for seborrheic dermatitis Dec 2023; launched Jan 2024.
- PDUFA target date July 7, 2024 for roflumilast cream 0.15% in atopic dermatitis.

## SEC filing metadata
- accession: 0001787306-24-000029
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730624000029/0001787306-24-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730624000029/arqt-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-24-000029
- JSON: https://secwatch.observer/filing/0001787306-24-000029.json
- Plain text: https://secwatch.observer/filing/0001787306-24-000029.txt

## Key facts
- Earnings Releases
  Arcutis Biotherapeutics, Inc. reported the quarter ended December 31, 2023 results: revenue $13.5 million.
  - Period: the quarter ended December 31, 2023
  - Revenue: $13.5 million
  - Result: reported results
  source text: --- Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • Q4 net product revenues for ZORYVE® (roflumilast) cream 0.3% were $13.5 million, a 357% increase compared to the fourth quarter of 2022 and a 67% increase compared to the third quarter of 2023; driven by sequential improvement in gross-to-net (GTN) in the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787306/000178730624000029/0001787306-24-000029-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.